1. New opioid data may not be generalizable, FDA adcomm says  Endpoints News
  2. Nearly Quarter of People on Long-Acting Opioids Develop Addiction  Bloomberg.com
  3. Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling  insights.citeline.com
  4. New Opioid Data May Not Reflect Harms Accurately, FDA Advisors Warn  MedPage Today
  5. US FDA Asks Adcomm If Opioid Postmarketing Studies Are Relevant, Warrant Action  insights.citeline.com